Introduction

Cyclic Vomiting Syndrome (CVS) is a functional gastroduodenal disorder characterized by recurrent, stereotypical episodes of intense nausea and vomiting separated by symptom-free or relatively symptom-free intervals. Each episode follows a recognizable pattern for the individual patient: an acute onset, a period of relentless vomiting that typically lasts hours to days (but less than one week), and a return to baseline health once the episode resolves. The Rome IV classification system, published in 2016, provides standardized diagnostic criteria for CVS in adults to facilitate consistent clinical identification and to distinguish the condition from other causes of recurrent vomiting.

Although CVS was historically considered a pediatric disorder, it is now well established that the condition persists into adulthood in many patients and can present de novo in adults at any age. Adult CVS is a significantly underdiagnosed condition: the mean time from symptom onset to correct diagnosis has been reported in the range of 5 to 10 years in multiple case series. During this diagnostic delay, patients commonly accumulate extensive emergency department visits, hospitalizations, imaging studies, endoscopies, and even unnecessary surgical procedures. The economic and psychosocial burden is substantial. Recognition of CVS as a distinct clinical entity, facilitated by the Rome IV criteria, is the essential first step toward appropriate management.

Historical Context and Evolution of the Diagnostic Criteria

Cyclic vomiting was first described in the medical literature by Samuel Gee in 1882, who reported a series of children with recurrent, self-limited episodes of intense vomiting. For over a century after Gee's description, CVS was regarded almost exclusively as a childhood condition, and many clinicians assumed that affected children simply "outgrew" the disorder at puberty. It was not until the 1990s and 2000s that systematic studies established CVS as a significant problem in adult populations.

The Rome classification system first addressed CVS in Rome II (1999), classifying it under functional gastroduodenal disorders. The Rome II criteria required stereotypical episodes of vomiting with acute onset and duration less than one week, three or more episodes in the prior year, and the absence of nausea and vomiting between episodes. Rome III (2006) refined these criteria modestly, retaining the same core structure but adjusting the language and adding the temporal requirement that criteria be fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.

The Rome IV revision (2016) preserved the fundamental diagnostic framework established in Rome II and III but introduced several important refinements:

• The episode frequency criterion was made more specific, requiring not only three or more episodes in the prior year but also at least two episodes in the past 6 months, occurring at least one week apart. This dual frequency threshold was added to ensure a minimum recurrence rate and to exclude isolated or very infrequent episodes.
• The inter-episode criterion was softened to acknowledge that while overt vomiting should be absent between episodes, other milder symptoms (nausea, abdominal discomfort, fatigue, anorexia) may persist between cycles without excluding the diagnosis. This change reflected the clinical reality that many CVS patients report low-grade inter-episode symptoms.
• A supportive (but not required) criterion was introduced: a personal or family history of migraine headaches. This formalized the long-recognized clinical association between CVS and migraine, while appropriately leaving it as supportive rather than mandatory.
• The temporal requirement was retained: criteria must be fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis, consistent with other Rome IV gastroduodenal disorders.

Epidemiology

The epidemiology of CVS in adults is incompletely characterized, in large part because the condition remains underrecognized and frequently misdiagnosed. Available data suggest the following patterns:

Prevalence

Population-based studies in adults are limited. Estimates of CVS prevalence in the general adult population range from approximately 0.5% to 2%, depending on the survey methodology, diagnostic criteria applied, and population studied. A large population-based study using Rome IV criteria across multiple countries reported a prevalence of approximately 0.5% to 1% for CVS in the adult population. These figures are almost certainly underestimates, given the high rate of misdiagnosis and the fact that many patients with CVS are classified under other diagnostic labels (e.g., "recurrent vomiting of unknown etiology," "abdominal migraine," or "gastroparesis") before the correct diagnosis is made.

Age and Sex Distribution

CVS can present at any age. In pediatric populations, peak onset is between ages 3 and 7 years. In adults, the condition may represent a continuation of childhood CVS (approximately 25% to 30% of pediatric CVS patients continue to have episodes into adulthood) or may present de novo. Adult-onset CVS has a peak incidence in the third and fourth decades of life, though onset has been reported in patients as old as their seventies.

In children, CVS affects boys and girls roughly equally. In adult populations, most case series report a female predominance, with female-to-male ratios in the range of 1.5:1 to 3:1. This sex distribution is consistent with the female predominance observed in migraine and in other functional gastrointestinal disorders.

Comorbidities and Associated Conditions

Several conditions are strongly associated with CVS:

• Migraine: The association between CVS and migraine is the most consistently reported comorbidity. Depending on the series, 30% to 70% of adult CVS patients have a personal history of migraine, and up to 80% have a family history of migraine in first-degree relatives. This association has led to the hypothesis that CVS is a "migraine equivalent" or part of the broader migraine spectrum (see Pathophysiology).
• Psychiatric comorbidity: Anxiety disorders (including generalized anxiety, panic disorder, and social anxiety), depression, and somatoform disorders are reported in 50% to 80% of adult CVS patients. Whether these are causal, consequential, or share common pathophysiologic roots with CVS remains debated.
• Autonomic dysfunction: Postural orthostatic tachycardia syndrome (POTS), vasovagal syncope, and other forms of autonomic dysregulation are overrepresented in CVS populations.
• Mitochondrial dysfunction: Maternal inheritance patterns and biochemical markers of mitochondrial dysfunction have been reported in subsets of CVS patients, particularly those with childhood onset. Specific mitochondrial DNA polymorphisms (16519T and 3010A) have been associated with CVS susceptibility.
• Atopic disease: Asthma, eczema, and allergic rhinitis are more common in CVS patients than in the general population, further strengthening the link to the migraine-atopy spectrum.
• Cannabis use: A significant proportion of adult CVS patients use cannabis, either as self-medication for nausea or recreationally. This creates a diagnostic challenge, as cannabinoid hyperemesis syndrome (CHS) can mimic CVS closely (see Differential Diagnosis).

Healthcare Utilization

CVS is associated with extraordinarily high healthcare utilization. Multiple studies have documented that adult CVS patients average 12 to 15 emergency department visits per year during active disease, with annual hospitalization rates of 3 to 6 admissions per patient. Mean annual healthcare costs for an individual with CVS have been estimated at $30,000 to $80,000 in the United States. The diagnostic delay (mean 5 to 10 years) compounds these costs, as patients undergo repeated, redundant testing during the undiagnosed period.

Pathophysiology

The pathophysiology of CVS is complex and multifactorial. No single mechanism fully accounts for the disorder, and it is likely that CVS represents a final common pathway arising from the convergence of genetic predisposition, neurobiological vulnerability, and environmental triggers.

The Migraine-CVS Spectrum

The strongest etiologic hypothesis links CVS to migraine through shared neurovascular mechanisms. The evidence for this connection includes:

• High prevalence of personal and family histories of migraine in CVS patients
• Shared triggers (stress, sleep deprivation, menstruation, fasting, certain foods)
• Shared prodromal symptoms (pallor, lethargy, anorexia, irritability)
• Responsiveness of CVS to migraine-prophylactic medications (tricyclic antidepressants, topiramate, propranolol)
• Coexistence of migraine headaches during or between CVS episodes in many patients
• Transition from CVS to migraine headaches during adolescence in some pediatric patients

The proposed neurovascular model holds that CVS episodes are triggered by cortical or brainstem events analogous to those in migraine. Cortical spreading depression or brainstem activation may trigger downstream autonomic and emetic cascades involving the hypothalamus, the nucleus tractus solitarius, the area postrema (the brainstem "vomiting center"), and vagal afferent/efferent pathways. The resulting emetic output is intense and self-sustaining for the duration of the episode.

Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation

Stress is the most commonly reported trigger for CVS episodes, and there is evidence that the HPA axis is dysregulated in many CVS patients. Elevated baseline levels of corticotropin-releasing factor (CRF), adrenocorticotropic hormone (ACTH), and cortisol have been documented in some CVS populations. CRF is a potent emetic agent that acts through central CRF receptors in the hypothalamus and brainstem, and it has been proposed that an exaggerated CRF-mediated stress response may initiate or amplify the emetic cascade in CVS.

Autonomic Nervous System Dysfunction

Abnormalities in autonomic function are frequently demonstrated in CVS patients using measures such as heart rate variability analysis, tilt table testing, and thermoregulatory sweat testing. A pattern of sympathetic predominance (or reduced parasympathetic tone) has been reported during inter-episode intervals, while a shift toward parasympathetic activation may occur during episodes. This autonomic imbalance may contribute to the GI dysmotility and emetic activation that characterize CVS episodes.

Mitochondrial Dysfunction

The observation that CVS has a maternal inheritance pattern in some families led to the investigation of mitochondrial DNA (mtDNA) as a susceptibility factor. Two mtDNA polymorphisms, 16519T (in the non-coding control region) and 3010A (in the 16S ribosomal RNA gene), have been associated with CVS, particularly in children. These polymorphisms may impair mitochondrial energy metabolism, reducing the threshold for triggering emetic cascades under conditions of metabolic stress (e.g., fasting, illness, exercise). Not all CVS patients carry these polymorphisms, and mitochondrial dysfunction likely represents one of several contributing pathways rather than a universal mechanism.

Central Sensitization and the Emetic Threshold

A unifying concept in CVS pathophysiology is the idea of a reduced emetic threshold. In susceptible individuals, genetic and neurobiological factors conspire to lower the threshold at which the brainstem emetic circuitry is activated. Environmental triggers (stress, sleep disruption, fasting, infection, menstruation) then push the system past this threshold, initiating a self-sustaining emetic episode. Once activated, the episode runs a stereotypical course before spontaneously terminating, presumably when the triggering stimulus subsides and inhibitory mechanisms restore homeostasis.

Clinical Phases of a CVS Episode

A hallmark of CVS is the predictable, stereotypical progression of each episode through distinct clinical phases. Recognizing these phases aids in diagnosis and in tailoring phase-specific management:

Phase 1: Prodrome

Many patients experience a prodromal phase lasting minutes to hours before the onset of vomiting. Prodromal symptoms may include pallor, lethargy, nausea (without vomiting), diaphoresis, anorexia, abdominal discomfort, anxiety, and irritability. Some patients learn to recognize their prodrome reliably and can identify the onset of an impending episode. This recognition is clinically important because abortive therapy is most effective when administered during the prodromal phase.

Phase 2: Emetic Phase

The emetic phase is characterized by intense, relentless nausea and forceful vomiting. The vomiting is typically high-frequency (up to 6 or more episodes per hour in severe cases) and may be accompanied by retching, abdominal pain, diarrhea, fever, leukocytosis, and prostration. Patients are often unable to retain any oral intake during this phase and may rapidly develop dehydration, electrolyte disturbances (hypokalemia, hypochloremic metabolic alkalosis), and hematemesis from Mallory-Weiss tears. The emetic phase typically lasts from several hours to several days, with a mean duration of 24 to 72 hours in most series. By Rome IV definition, the duration is less than one week.

Phase 3: Recovery

The recovery phase begins when vomiting ceases and the patient gradually regains the ability to tolerate oral intake. Recovery may be abrupt or gradual, lasting hours to days. Patients often report profound fatigue, muscle soreness, and anorexia during this phase.

Phase 4: Inter-Episode (Well) Phase

Between episodes, the patient returns to baseline health with no vomiting. Rome IV acknowledges that milder symptoms, including low-grade nausea, abdominal discomfort, fatigue, and dyspepsia, may persist between episodes in some patients. The key distinction is the absence of overt vomiting during the inter-episode period. In some patients, the inter-episode intervals are completely asymptomatic; in others, there is a background level of functional GI symptoms that does not rise to the severity of an active episode.

The Rome IV Diagnostic Criteria: Detailed Breakdown

The Rome IV diagnostic criteria for CVS in adults require that all of the following be present, with criteria fulfilled for the last 3 months and symptom onset at least 6 months before diagnosis:

Criterion 1: Stereotypical Episodes of Vomiting Regarding Onset (Acute) and Duration (Less Than One Week)

This criterion captures the hallmark clinical feature of CVS: each episode follows a recognizable, repetitive pattern that is characteristic for that individual patient. The stereotypy may involve consistent time of onset (e.g., early morning, nocturnal), consistent prodromal symptoms, similar duration, similar intensity of vomiting, similar associated symptoms, and similar triggers.

Key elements of this criterion:

• Stereotypical: The patient (and often family members or caregivers) can describe a recognizable pattern to the episodes. While episodes need not be identical, they should share enough common features to be recognizable as recurrences of the same process. This distinguishes CVS from sporadic or random episodes of vomiting due to diverse causes.
• Acute onset: Episodes begin abruptly, often transitioning from apparent health (or from a brief prodrome) to intense vomiting within minutes. This rapid onset distinguishes CVS from conditions such as gastroparesis, in which nausea and vomiting tend to develop more gradually.
• Duration less than one week: Individual episodes are self-limited, typically lasting hours to days. The upper limit of one week provides a boundary that distinguishes CVS from chronic, continuous vomiting disorders (such as CNVS) and from conditions associated with prolonged vomiting (such as prolonged gastric outlet obstruction).

In clinical practice, asking the patient to describe their "typical episode" from start to finish, and then asking whether subsequent episodes followed a similar pattern, is the most effective way to assess this criterion.

Criterion 2: Three or More Discrete Episodes in the Prior Year and Two in the Past 6 Months, Occurring at Least One Week Apart

This criterion establishes a minimum recurrence rate that ensures the episodic nature of the condition is well established and not a chance occurrence. The dual frequency requirement (three in 12 months and two in 6 months) is more stringent than the Rome III criterion, which required only three episodes in the prior year.

Key elements:

• Three or more episodes in the prior year: Ensures a sufficient number of episodes to establish a pattern. Fewer than three episodes may represent isolated incidents or the early stages of CVS before the full pattern has declared itself.
• Two or more episodes in the past 6 months: Ensures that the condition is currently active, not in a prolonged remission phase. This prevents the diagnosis from being applied to patients whose episodes may have resolved spontaneously or with treatment.
• At least one week apart: Each episode must be separated from the next by a minimum of one week, ensuring that what is being counted are truly discrete events rather than a single prolonged episode with fluctuating intensity. This criterion also helps distinguish CVS from conditions such as cannabinoid hyperemesis syndrome, in which vomiting may occur in a more continuous or semi-continuous pattern with shorter intervals.

Patients should be asked to reconstruct a timeline of their episodes over the past year, including approximate dates, duration, and severity. A vomiting episode diary is extremely helpful for documenting frequency prospectively.

Criterion 3: Absence of Vomiting Between Episodes, but Other Milder Symptoms Can Be Present Between Cycles

This criterion defines the cardinal inter-episode feature of CVS: the patient returns to a baseline state in which overt vomiting does not occur. This on-off, episodic pattern is the single most distinguishing feature of CVS and separates it from chronic nausea vomiting syndrome (CNVS), in which nausea and/or vomiting are persistent and continuous.

The Rome IV refinement, which explicitly allows for milder inter-episode symptoms, is an important practical acknowledgment. Many CVS patients do experience some degree of background nausea, dyspepsia, abdominal discomfort, or fatigue between episodes. These inter-episode symptoms should not exclude the diagnosis, provided that there is a clear qualitative and quantitative distinction between the patient's baseline state and an active episode. The critical feature is the absence of vomiting during the inter-episode period.

Questions that help assess this criterion include:

• "Between your episodes, are you completely well, or do you have any ongoing symptoms?"
• "Between episodes, do you ever vomit?"
• "Can you clearly tell the difference between when you are in an episode and when you are between episodes?"

Criterion 4: Criteria Fulfilled for the Last 3 Months with Symptom Onset at Least 6 Months Before Diagnosis

This temporal criterion imposes two requirements:

• Active symptoms for 3 months: The episodic vomiting pattern must have been present for the most recent 3-month period. This does not require that an episode occurs within every 3-month window, but rather that the overall episodic pattern has been active and ongoing during this timeframe.
• Total symptom duration of at least 6 months: The first CVS episode must have occurred at least 6 months before the time of diagnosis. This requirement excludes patients with very recent-onset episodic vomiting, for whom an organic or structural cause is more likely and for whom the diagnostic pattern may not yet be fully established.

The dual temporal requirement serves as a safeguard against premature diagnosis. Conditions such as intermittent small bowel obstruction, intermittent volvulus, pheochromocytoma, and recurrent pancreatitis can present with episodic vomiting that mimics CVS, and these conditions may only be identified with observation over time or with targeted investigations prompted by atypical features.

The Supportive Criterion: Migraine History

Rome IV includes one supportive (but not required) criterion: a personal or family history of migraine headaches. This criterion was added to formalize the strong clinical and epidemiologic association between CVS and migraine. Its presence increases diagnostic confidence but is not mandatory, and many CVS patients do not have a migraine history.

In clinical practice, the migraine history should be assessed by asking:

• "Do you have a personal history of migraine headaches?"
• "Does anyone in your immediate family (parents, siblings) have migraines?"
• "As a child, did you experience motion sickness, abdominal migraine, or recurrent vomiting episodes?"

The presence of a migraine history, especially when combined with other migraine-spectrum features (prodromal pallor, photophobia or phonophobia during episodes, response to triptans or migraine prophylactics), strengthens the clinical suspicion for CVS and may guide therapeutic selection toward migraine-oriented treatments.

Triggers and Precipitating Factors

Many CVS patients can identify specific triggers that precipitate episodes. Recognizing and avoiding triggers is a cornerstone of CVS management. Commonly reported triggers include:

Trigger Category	Specific Triggers
Psychological stress	Emotional distress, anxiety, panic, excitement (both positive and negative emotional arousal), anticipatory stress
Physiological stress	Infection (particularly upper respiratory infections and gastroenteritis), physical exhaustion, overexertion, surgery
Sleep	Sleep deprivation, irregular sleep schedules, jet lag
Dietary	Fasting, overeating, specific foods (chocolate, cheese, monosodium glutamate, caffeine), alcohol
Hormonal	Menstruation (catamenial CVS), ovulation
Environmental	Motion, heat, weather changes
Substances	Cannabis (paradoxically, in some patients), opioids, anesthetic agents

Approximately 80% of adult CVS patients can identify at least one trigger, and many report multiple triggers. A trigger diary is a valuable clinical tool for identifying patterns and guiding avoidance strategies.

Differential Diagnosis

The differential diagnosis of recurrent, episodic vomiting is broad, and a systematic approach is essential to avoid both underdiagnosis of CVS (leading to unnecessary procedures and prolonged morbidity) and overdiagnosis (which could result in missing a serious organic condition).

Condition	Key Distinguishing Features
Cannabinoid hyperemesis syndrome (CHS)	Clinically mimics CVS closely. Occurs in the setting of chronic, heavy cannabis use (typically daily use for at least 1 year). Compulsive hot water bathing is a classic feature (present in approximately 50-70% of cases). Symptoms resolve with sustained cannabis cessation. A 2-4 week trial of cannabis abstinence is the key diagnostic maneuver. Urine toxicology may be helpful.
Chronic Nausea Vomiting Syndrome (CNVS)	Nausea and/or vomiting are chronic and persistent rather than episodic. There is no clear on-off pattern or return to baseline between episodes. CNVS represents the "chronic" end of the nausea-vomiting spectrum, while CVS represents the "episodic" end.
Gastroparesis	Nausea, vomiting, early satiety, bloating, and postprandial discomfort. Symptoms are typically chronic and meal-related rather than episodic. Delayed gastric emptying on scintigraphy (>10% retention at 4 hours). Episodes of exacerbation may occur but do not follow the stereotypical, discrete pattern of CVS.
Intestinal malrotation with intermittent volvulus	Recurrent episodes of bilious vomiting and abdominal pain. May closely mimic CVS. Upper GI series may show abnormal positioning of the duodenojejunal junction. Should be considered in any patient with recurrent vomiting of unclear etiology, particularly if episodes include bilious vomiting or severe abdominal pain.
Superior mesenteric artery (SMA) syndrome	Compression of the duodenum by the SMA, causing postprandial nausea, vomiting, and epigastric pain. Often in thin individuals or those with recent weight loss. CT angiography demonstrates reduced aortomesenteric angle and distance.
Recurrent pancreatitis	Episodic severe epigastric pain radiating to the back, accompanied by nausea and vomiting. Elevated lipase and/or amylase during episodes. Imaging may show pancreatic changes.
Adrenal insufficiency	Episodic nausea, vomiting, fatigue, hypotension, and electrolyte abnormalities (hyponatremia, hyperkalemia). Morning cortisol and cosyntropin stimulation testing are diagnostic.
Pheochromocytoma/paraganglioma	Episodic hypertension, headache, diaphoresis, palpitations, and nausea/vomiting. Plasma or urine fractionated metanephrines are the screening test of choice.
Central nervous system pathology	Posterior fossa tumors, Chiari malformation, hydrocephalus, and increased intracranial pressure can present with recurrent vomiting. Headache, papilledema, and neurological deficits should prompt neuroimaging.
Metabolic disorders	Acute intermittent porphyria, urea cycle defects, fatty acid oxidation disorders, and other inborn errors of metabolism can present with episodic vomiting, particularly in younger patients. Targeted metabolic testing is indicated when the history suggests these possibilities.
Abdominal epilepsy	Rare. Recurrent episodes of abdominal pain, nausea, and vomiting associated with EEG abnormalities. Episodes may respond to antiepileptic medications.

Clinical Evaluation and Diagnostic Approach

The diagnosis of CVS under the Rome IV framework is primarily clinical, based on a detailed history that confirms the stereotypical, episodic pattern and appropriate exclusion of organic causes. A systematic evaluation should proceed as follows:

Step 1: Comprehensive History

The clinical history is the most powerful diagnostic tool in CVS. Key elements include:

• Episode characterization: Ask the patient to describe a "typical episode" in detail: onset (abrupt vs. gradual), prodromal symptoms, duration, frequency and intensity of vomiting, associated symptoms (abdominal pain, diarrhea, headache, photophobia, pallor, diaphoresis), and resolution pattern
• Episode timeline: Reconstruct a chronological history of all episodes over the past 1 to 2 years, including approximate dates, duration of each, and any periods of remission
• Inter-episode state: Specifically ask whether the patient vomits between episodes, and whether they return to a recognizable baseline
• Triggers: Systematically review known trigger categories (stress, sleep, diet, menstruation, illness, cannabis)
• Cannabis use history: Detailed and non-judgmental inquiry into cannabis use patterns (frequency, duration, method of consumption, relationship of use to episodes). This is essential to differentiate CVS from CHS.
• Migraine history: Personal and family history of migraine, childhood motion sickness, abdominal migraine
• Medication history: All current medications, recent changes, and use of emetogenic agents
• Psychiatric history: Screen for anxiety, depression, panic disorder, and history of trauma or adverse childhood experiences
• Surgical history: Prior abdominal surgeries (particularly cholecystectomy, appendectomy, and exploratory laparotomy performed during undiagnosed CVS episodes)
• Family history: Migraine, CVS, irritable bowel syndrome, and other functional GI disorders in first-degree relatives

Step 2: Physical Examination

Between episodes, the physical examination is typically normal. During episodes, patients may appear acutely ill, dehydrated, and distressed. The inter-episode examination should assess:

• General appearance, nutritional status, and weight
• Vital signs, including orthostatic measurements
• Abdominal examination for tenderness, distension, masses, succussion splash, or surgical scars
• Dental examination for enamel erosion from chronic acid exposure
• Neurological screening (cranial nerves, fundoscopic examination, cerebellar signs) to exclude posterior fossa or CNS pathology
• Skin examination for signs of systemic disease (hyperpigmentation suggesting adrenal insufficiency, flushing suggesting carcinoid)

Step 3: Laboratory Evaluation

Baseline laboratory testing should include:

• Complete blood count (CBC)
• Comprehensive metabolic panel (electrolytes, glucose, BUN, creatinine, hepatic function tests, calcium)
• Lipase (to exclude recurrent pancreatitis)
• Thyroid-stimulating hormone (TSH)
• Morning cortisol or cosyntropin stimulation test (to exclude adrenal insufficiency)
• Pregnancy test (in women of reproductive age)
• Urine drug screen, including cannabinoids
• Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)
• Plasma or 24-hour urine fractionated metanephrines (if episodic hypertension or other features suggest pheochromocytoma)

Additional metabolic testing (urine porphyrins, urine organic acids, plasma amino acids, acylcarnitine profile) should be considered in younger patients, those with episodic neurological symptoms, or those with atypical features suggesting a metabolic disorder.

Step 4: Upper Endoscopy

While not explicitly mandated by the Rome IV criteria for CVS (as it is for CNVS), upper endoscopy is recommended in the initial evaluation to exclude peptic ulcer disease, eosinophilic esophagitis, gastric outlet obstruction, and other structural causes. Biopsies of the esophagus, stomach, and duodenum should be obtained per standard protocol.

Step 5: Additional Imaging and Testing

Depending on the clinical picture, additional testing may include:

• Abdominal CT or MRI: To evaluate for malrotation, SMA syndrome, pancreaticobiliary pathology, or abdominal masses
• Upper GI series with small bowel follow-through: Particularly valuable for evaluating malrotation and partial small bowel obstruction
• Gastric emptying scintigraphy: To differentiate from gastroparesis; should be performed between episodes, not during an acute episode
• Brain MRI: If headache, papilledema, neurological symptoms, or atypical features raise concern for CNS pathology
• Autonomic testing: Tilt table test and heart rate variability analysis if POTS or autonomic dysfunction is suspected

Treatment and Management

The management of CVS is phase-specific, addressing the distinct therapeutic needs of the prodromal, emetic, recovery, and inter-episode phases. A comprehensive management strategy combines lifestyle modifications, trigger avoidance, prophylactic pharmacotherapy, abortive therapy, and supportive care during episodes.

Lifestyle Modifications and Trigger Avoidance

Trigger avoidance is the foundation of CVS management and should be addressed with every patient:

• Sleep hygiene: Regular sleep schedule, adequate sleep duration, avoidance of sleep deprivation
• Stress management: Stress reduction techniques, cognitive behavioral therapy, and treatment of comorbid anxiety and depression
• Dietary regularity: Regular meal timing, avoidance of prolonged fasting, avoidance of known dietary triggers
• Cannabis cessation: Complete cessation is recommended for all CVS patients who use cannabis, both because cannabis can trigger episodes in some patients and because ongoing use makes it impossible to exclude CHS as the diagnosis
• Exercise moderation: Avoidance of intense physical exertion that has been identified as a trigger

Prophylactic (Preventive) Therapy

Prophylactic medications are indicated for patients with frequent (four or more episodes per year), severe, or prolonged CVS episodes. The goal is to reduce episode frequency, severity, and duration. First-line prophylactic agents include:

• Tricyclic antidepressants (TCAs): Amitriptyline is the most widely used and best-studied prophylactic agent for CVS. Dosing typically begins at 10 to 25 mg at bedtime and is titrated upward over weeks to a target dose of 50 to 150 mg (or the maximum tolerated dose). TCAs are thought to exert their benefit through modulation of central emetic pathways, serotonergic and noradrenergic neurotransmission, and migraine-preventive mechanisms. Nortriptyline may be used as an alternative with a somewhat more favorable side-effect profile.
• Topiramate: An anticonvulsant with established migraine prophylactic efficacy. Dosing is typically 25 to 100 mg twice daily. Topiramate is a reasonable alternative for patients who cannot tolerate TCAs. Side effects include cognitive dulling, paresthesias, weight loss, and renal calculi.
• Propranolol: A non-selective beta-blocker with migraine-preventive properties. More commonly used in pediatric CVS; evidence in adults is limited but clinical experience supports its use in select patients, particularly those with comorbid migraine and anxiety. Dosing is typically 10 to 40 mg two to three times daily.
• Coenzyme Q10 and L-carnitine: Mitochondrial supplements that are used based on the mitochondrial dysfunction hypothesis. Evidence is primarily from pediatric studies and case series. CoQ10 is typically dosed at 10 mg/kg/day (up to 200 mg twice daily in adults), and L-carnitine at 50 mg/kg/day (up to 1000 mg three times daily). These supplements are generally well tolerated and may be used alone (for mild CVS) or in combination with other prophylactics.

Abortive (Acute Episode) Therapy

Abortive therapy aims to terminate a CVS episode as early as possible, ideally during the prodromal phase before full emetic onset. Agents used for abortive therapy include:

• Triptans: Sumatriptan (subcutaneous, intranasal, or oral) and zolmitriptan (intranasal or oral) are the most commonly used abortive agents for CVS, reflecting the migraine-CVS connection. Triptans are most effective when administered during the prodrome, before vomiting begins. Once vomiting is established, the oral route may be unreliable due to impaired absorption, and subcutaneous or intranasal administration is preferred.
• Ondansetron: A 5-HT3 receptor antagonist that may provide symptomatic relief from nausea but often has limited efficacy in aborting a full CVS episode. Available in oral, intravenous, and orally disintegrating tablet formulations.
• Lorazepam: A benzodiazepine that may reduce the intensity of emetic episodes, possibly through anxiolytic effects and sedation. Often used as an adjunct during severe episodes. Dosing is typically 0.5 to 1 mg sublingual or intravenous.

Supportive Care During Episodes

During severe emetic episodes, many patients require emergency department evaluation and/or hospitalization for supportive care:

• Intravenous fluid resuscitation: Isotonic saline with electrolyte repletion (particularly potassium and magnesium) to correct dehydration and metabolic alkalosis
• Antiemetics: Ondansetron (IV), prochlorperazine (IV/IM), or promethazine (IV/IM). Combination therapy may be necessary for refractory symptoms.
• Sedation: Diphenhydramine, lorazepam, or low-dose haloperidol may be used for sedation in severely distressed patients, with the goal of allowing the patient to "sleep through" the episode.
• Pain management: NSAIDs (ketorolac IV) for associated abdominal pain or headache. Opioids should be avoided if possible due to their emetogenic properties and the risk of narcotic bowel syndrome and opioid dependence, both of which are disproportionately common in the CVS population.
• Proton pump inhibitor: IV pantoprazole or oral PPI to protect against esophageal and gastric mucosal injury from repeated vomiting and to reduce the discomfort of acid exposure.

An individualized emergency care plan, prepared in advance and shared with the patient's local emergency department, can dramatically improve the efficiency and appropriateness of acute care during CVS episodes.

Behavioral and Psychological Therapies

Given the high prevalence of psychiatric comorbidity and the role of stress as a trigger, behavioral interventions are an important component of CVS management:

• Cognitive behavioral therapy (CBT): Targets maladaptive thought patterns, anticipatory anxiety about episodes, and avoidance behaviors. CBT can reduce episode frequency by improving stress management and coping strategies.
• Biofeedback and relaxation training: Progressive muscle relaxation, diaphragmatic breathing, and guided imagery may help modulate autonomic arousal and reduce the likelihood of stress-triggered episodes.
• Mindfulness-based stress reduction (MBSR): Emerging evidence supports mindfulness approaches for functional GI disorders, though specific data in CVS are limited.

Complications

CVS can lead to significant medical complications, particularly when episodes are frequent, severe, or inadequately managed:

• Dehydration and electrolyte disturbances: The most immediate concern during emetic episodes. Hypokalemia, hypochloremic metabolic alkalosis, hypomagnesemia, and prerenal azotemia are common. Severe electrolyte imbalances can cause cardiac arrhythmias.
• Mallory-Weiss tears: Mucosal lacerations at the gastroesophageal junction from forceful retching, presenting as hematemesis. Most are self-limited, but severe tears may require endoscopic intervention.
• Dental erosion: Chronic acid exposure from recurrent vomiting causes irreversible enamel erosion, dental caries, and dentinal hypersensitivity.
• Esophagitis and Barrett esophagus: Chronic acid exposure may produce erosive esophagitis. Whether the risk of Barrett esophagus is elevated in CVS patients is not well studied, but chronic acid injury to the distal esophagus is a theoretical concern.
• Nutritional deficiencies and weight loss: Recurrent caloric losses, dietary restriction during and between episodes, and malabsorption can produce protein-calorie malnutrition and micronutrient deficiencies.
• Opioid dependence: Repeated emergency department presentations with severe pain and vomiting frequently result in opioid administration. Chronic opioid use can exacerbate GI dysfunction (opioid-induced nausea, gastroparesis, narcotic bowel syndrome) and create a cycle of dependence that complicates CVS management.
• Psychosocial impairment: CVS has a profound impact on quality of life, employment, education, social relationships, and psychological well-being. Many patients report losing jobs, dropping out of school, and social isolation as a result of unpredictable, disabling episodes.
• Unnecessary surgical procedures: During the undiagnosed phase, CVS patients frequently undergo cholecystectomy, appendectomy, or exploratory laparotomy for presumed surgical causes of their episodic abdominal pain and vomiting. These procedures do not resolve CVS symptoms and expose patients to surgical risks.

Special Considerations

CVS and Cannabis: The CHS Diagnostic Challenge

Differentiating CVS from cannabinoid hyperemesis syndrome (CHS) is one of the most important and clinically challenging tasks in evaluating patients with recurrent episodic vomiting. The overlap is substantial: both conditions produce stereotypical episodes of severe nausea and vomiting, and many CVS patients use cannabis (either recreationally or as self-medication for inter-episode nausea). Key distinguishing features include:

• Cannabis use pattern: CHS typically requires chronic, heavy cannabis use (usually daily use for at least 1 year), though cases with less exposure have been reported.
• Hot water bathing: Compulsive bathing in hot water for symptom relief is a classic CHS feature, reported in 50% to 70% of cases. It is not a feature of CVS.
• Cannabis cessation response: CHS resolves with sustained cannabis cessation (typically within 1 to 3 months). CVS does not resolve with cannabis cessation.
• Migraine association: A personal or family history of migraine supports CVS over CHS.

For any patient who uses cannabis and presents with episodic vomiting, a supervised trial of complete cannabis abstinence (minimum 2 to 4 weeks, ideally 2 to 3 months) is the most reliable diagnostic maneuver. If episodes resolve, CHS is the likely diagnosis. If episodes persist despite confirmed abstinence, CVS is more likely.

CVS in the Emergency Department

Emergency department management of CVS is often suboptimal because the condition is unfamiliar to many emergency physicians and because the intense symptomatology of an acute episode may prompt extensive, redundant diagnostic testing. Proactive measures to improve emergency care include:

• An individualized emergency care letter signed by the patient's gastroenterologist, describing the diagnosis, recommended treatments, and medications to avoid
• An established protocol for IV fluids, antiemetics, and sedation
• Clear guidance to avoid unnecessary abdominal CT scans and opioids unless specific new indications arise
• Documentation in the electronic medical record to ensure continuity across visits

CVS and Pregnancy

Pregnancy may alter the course of CVS. Some women experience worsening of episodes during pregnancy, while others report improvement or remission. The management of CVS during pregnancy requires careful attention to medication safety (many CVS prophylactics are contraindicated or require caution), hydration, nutritional support, and coordination between gastroenterology and obstetrics.

Overlap with Other Functional GI Disorders

CVS commonly overlaps with other functional gastrointestinal disorders. Between episodes, many CVS patients meet criteria for functional dyspepsia, irritable bowel syndrome, or chronic nausea vomiting syndrome. The Rome IV framework permits the coexistence of multiple FGID diagnoses, and management should address each symptom domain. Neuromodulators such as amitriptyline may provide benefit across multiple overlapping conditions.

Refractory CVS

A subset of CVS patients (estimated at 10% to 20%) have episodes that are refractory to standard prophylactic and abortive therapies. Management strategies for refractory CVS include:

• Combination prophylactic therapy (e.g., TCA plus topiramate, or TCA plus CoQ10/L-carnitine)
• Aprepitant (a neurokinin-1 receptor antagonist) as prophylaxis or abortive therapy
• Referral to a specialized neurogastroenterology or motility center
• Intensive behavioral health support
• Re-evaluation for missed organic diagnoses, particularly if the clinical pattern changes or if new features emerge

Prognosis

The natural history of CVS in adults is variable. Some patients experience spontaneous remission over years, while others have persistent, lifelong episodes. With appropriate prophylactic therapy, the majority of patients experience a significant reduction in episode frequency and severity. Studies have reported a 50% to 75% reduction in episode frequency with TCA prophylaxis, and many patients achieve complete or near-complete remission.

Factors associated with a less favorable prognosis include chronic daily cannabis use, coexisting psychiatric illness (particularly severe anxiety or depression), coexisting chronic pain syndromes, opioid dependence, and poor adherence to prophylactic therapy. Early diagnosis, appropriate prophylaxis, trigger avoidance, behavioral health support, and a collaborative patient-physician relationship are the key determinants of long-term outcomes.

How This Calculator Works

This calculator applies the Rome IV diagnostic criteria for Cyclic Vomiting Syndrome in a structured, stepwise format. The user evaluates whether each of the four required criteria is met based on the clinical history and findings. All required criteria must be fulfilled for a positive diagnosis. The calculator also assesses the supportive criterion (personal or family history of migraine), which, when present, increases diagnostic confidence but is not required for the diagnosis.

The output provides a clear determination of whether the Rome IV criteria are met, a detailed breakdown of each required and supportive criterion, and contextual clinical guidance. This tool is intended for educational purposes and clinical decision support only. It does not replace clinical judgment, and all diagnostic and management decisions should be made by a qualified healthcare provider in the context of the individual patient.